Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
| 対象疾患 | Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer |
|---|---|
| 相 | 第2相 |
| スポンサー | Beth Israel Deaconess Medical Center |
| ステータス | 早期終了 |
| 参加者数 | 15 名 |
| 介入（薬剤） | GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod |
| 開始日 | 2008年5月 |
| 完了日 | 2025年8月 |
| 結果公開日 | 2026年8月5日 |
概要
This research study is evaluating the effect (good and bad) of a dendritic cell/tumor fusion vaccine in combination with the laboratory made agents GM-CSF and imiquimod on the participants immune system. Another purpose of this study is to determine the type and severity of any side effects associated with this new study vaccine. We will also be evaluating what effect the vaccine has on the participants cancer. Dendritic cell vaccines have already been tested in clinical trials involving participants with many different types of cancer. Dendritic cells are powerful immune-stimulating cells that are normally found in small amounts in the body and are responsible for immune responses against "foreign" substances that enter the body.
Determine if Cellular Immunity is Induced
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)
- Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Can — National Cancer Institute (NCI)